In August 2012, the Pharmacy and Therapeutics Committee reviewed three new items of business:

**New items of business**

1. Formulary Interchange: Renagel to Renvela
2. Formulary Medication Request: Relistor (Methylnaltrexone Bromide)
3. Pharmacist EPIC Ordering Options: Scope of Practice

A brief summary of each pertinent business item is below.

**Formulary Interchange: Renagel to Renvela**

The Pharmacy and Therapeutics Committee accepted the Department of Pharmacy's recommendation to **remove** Renagel (sevelamer hydrochloride) and **add** Renvela (sevelamer carbonate). Both Renvela and Renagel are phosphate binders utilized for the control of phosphate levels in chronic kidney disease patients. Renvela has similar efficacy with improved cost savings, side effect profile, and bicarbonate levels when compared to Renagel. Renvela is available only as an 800 mg tablet as a formulary agent. The powder for reconstitution dosage form will remain non-formulary. The Pharmacy and Therapeutics Committee also accepted a therapeutic interchange for all Renagel orders to be converted to Renvela (see below).

All doses for Renagel should be converted to Renvela on a tablet per tablet basis. Renagel comes as a 400 mg or 800 mg tablet whereas Renvela is only available as an 800 mg tablet (e.g. Renagel 1200 mg tid would be automatically converted by the pharmacist to Renvela 1600 mg tid)

<table>
<thead>
<tr>
<th><strong>Sevelamer Hydrochloride (Renagel)</strong></th>
<th><strong>Sevelamer Carbonate (Renvela)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>400 mg</td>
<td>800 mg</td>
</tr>
<tr>
<td>800 mg</td>
<td>800 mg</td>
</tr>
<tr>
<td>1200 mg</td>
<td>1600 mg</td>
</tr>
<tr>
<td>1600 mg</td>
<td>1600 mg</td>
</tr>
<tr>
<td>2000 mg</td>
<td>2400 mg</td>
</tr>
<tr>
<td>2400 mg</td>
<td>2400 mg</td>
</tr>
<tr>
<td>2800 mg</td>
<td>3200 mg</td>
</tr>
<tr>
<td>3200 mg</td>
<td>3200 mg</td>
</tr>
</tbody>
</table>
Relistor (Methylnaltrexone Bromide)

Relistor (methylnaltrexone bromide) was reviewed by the Pharmacy and Therapeutics Committee. The committee voted not to add this agent to the medication formulary at UMMC and remain as a non-formulary agent.

Pharmacist EPIC Ordering Options: Scope of Practice

Pharmacists at UMMC have historically altered physician orders when there was not a change in clinical intent and have streamlined orders that did not belong on the patient profile. The Pharmacy and Therapeutics Committee accepted the Department of Pharmacy’s request for the development of two additional ordering options for pharmacists that do not require co-signature to provide these same functions with EPIC. These functions are listed below:

1) Order adjustment with no change in clinical intent (see packet for examples)
   a. Combo product to individual components
   b. Change in medication strength, package size, dosage formulation
   c. Adjustment of dosing schedule if not able to accomplish by normal routines
   d. Medication related fluid change (volume and type)

2) Administrative adjustment (see packet for examples)
   a. D/C medications that have not fallen of the MAR (i.e. on call, PACU, one time orders)
   b. Identical duplicate orders

When workflow as stated above needs to be addressed, the pharmacist should utilize the “per protocol, no cosign required” function.